Stock GSS GENETIC SIGNATURES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Genetic Signatures Limited Share Price

Equities

GSS

AU000000GSS4

Advanced Medical Equipment & Technology

Market Closed - Australian S.E.
Other stock markets
 11:40:43 01/05/2024 am IST 		5-day change 1st Jan Change
0.7 AUD +0.72% Intraday chart for Genetic Signatures Limited +2.94% +60.92%
30/04 Genetic Signatures Appoints Interim CEO MT
28/04 Genetic Signatures' Sales Drop in Fiscal Q3 MT

Financials

Sales 2024 * 10.1M 6.55M 546M Sales 2025 * 26.2M 16.98M 1.42B Capitalization 130M 84.01M 7.01B
Net income 2024 * -17M -11.02M -919M Net income 2025 * -6M -3.89M -325M EV / Sales 2024 * 10.9 x
Net cash position 2024 * 20M 12.96M 1.08B Net cash position 2025 * 7M 4.54M 379M EV / Sales 2025 * 4.68 x
P/E ratio 2024 *
-7.39 x
P/E ratio 2025 *
-19.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.08%
More Fundamentals * Assessed data

Chart Genetic Signatures Limited

Dynamic Chart

Latest news about Genetic Signatures Limited

Genetic Signatures Appoints Interim CEO MT
Genetic Signatures' Sales Drop in Fiscal Q3 MT
Genetic Signatures Secures TGA Approval for Updated EasyScreen Respiratory Pathogen Detection Kit Sale in Australia MT
Genetic Signatures Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Genetic Signatures Completes Rights Issue MT
Genetic Signatures Closes AU$8 Million Placement MT
Genetic Signatures to Raise AU$15.9 Million via Placement MT
Genetic Signatures Raises AU$16 Million From Share Sale MT
Genetic Signatures Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023 MT
Genetic Signatures Limited Appoints Stephane Chatonsky as Director CI
Genetic Signatures Fiscal Q1 Sales Fall 64% Due to Performance Issue MT
Genetic Signatures Limited(ASX:GSS) dropped from S&P/ASX Emerging Companies Index CI
Genetic Signatures Submits 510(k) Application to the US FDA to Market Parasite Detection Kit in the US; Shares Jump 17% MT
Genetic Signatures Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Genetic Signatures Appoints CFO/COO MT
More news

Press releases Genetic Signatures Limited

Genetic Signatures : Quarterly update and Appendix 4C PU
Genetic Signatures : Application for quotation of securities - GSS PU
Genetic Signatures : Company presentation PU
Genetic Signatures : Application for quotation of securities - GSS PU
Genetic Signatures : Investor presentation PU
More press releases

Quotes and Performance

1 day+0.72%
1 week+2.94%
Current month+2.94%
1 month+3.70%
3 months+42.86%
6 months+40.00%
Current year+60.92%
More quotes

Highs and lows

1 week
0.63
Extreme 0.625
0.70
1 month
0.63
Extreme 0.625
0.72
Current year
0.41
Extreme 0.405
0.75
1 year
0.38
Extreme 0.38
0.75
3 years
0.38
Extreme 0.38
1.86
5 years
0.38
Extreme 0.38
2.94
10 years
0.24
Extreme 0.235
2.94
More quotes

Managers and Directors - Genetic Signatures Limited

Managers TitleAgeSince
John Melki CEO
 Chief Executive Officer - 01/03/01
Karl Pechmann DFI
 Director of Finance/CFO - 26/23/26
Douglas Millar CTO
 Chief Tech/Sci/R&D Officer - 15/01/15
Members of the board TitleAgeSince
Anthony Radford BRD
 Director/Board Member - 15/15/15
Caroline Waldron BRD
 Director/Board Member - 13/22/13
Michael Aicher BRD
 Director/Board Member 64 02/14/02
More insiders

Quotes

Date Price Change Volume
01/24/01 0.7 +0.72% 23 967
30/24/30 0.695 -0.71% 107,446
29/24/29 0.7 +2.19% 96,719
26/24/26 0.685 +0.74% 71,242
24/24/24 0.68 0.00% 75,859

Delayed Quote Australian S.E., May 01, 2024 at 11:40 am IST

More quotes

Company Profile

Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company’s principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit and others.
Sector
Advanced Medical Equipment & Technology
Calendar
28/08/2024 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Genetic Signatures Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.695 AUD
Average target price
0.75 AUD
Spread / Average Target
+7.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
GENETIC SIGNATURES LIMITED Stock Genetic Signatures Limited
+60.92% 84.17M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.15% 217B
DANAHER CORPORATION Stock Danaher Corporation
+6.60% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+9.86% 131B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+24.32% 106B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-0.95% 62.16B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+11.04% 51.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.81% 50.89B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-1.43% 40.16B
RESMED, INC. Stock ResMed, Inc.
+24.40% 31.44B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. GSS Stock